📰 Per Protocol News
Page 3 - Per Protocol News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Per Protocol. Real-time updates on events, politics, business and more.
November 21, 2022
Biophytis (NASDAQ:BPTS, EPA:ALBPS) CEO Stanislas Veillet joined Steve Darling from Proactive to share news the company has released the full results from...
November 21, 2022
Biophytis (NASDAQ:BPTS, EPA:ALBPS) CEO Stanislas Veillet joined Steve Darling from Proactive to share news the company has released the full results from...
November 3, 2022
03.11.2022 - Biophytis / Key word(s): Study results Biophytis reports positive post-hoc analysis of the phase 2-3 COVA clinical study strongly supporting therapeutic potential of Sarconeos (BIO101) in COVID-19 03-Nov-2022 / 08:00 CET/CEST Biophytis reports ... Seite 1
November 3, 2022
Biophytis / Key word(s): Study resultsBiophytis reports positive post-hoc analysis of the phase 2-3 COVA clinical study strongly supporting therapeutic potential of Sarconeos (BIO101) in COVID-19 03-Nov-2022 / 08:00 CET/CEST Biophytis reports positive post-hoc analysis of the phase 2-3 COVA clinical study stron...
May 16, 2022
16.05.2022 - Synairgen plc (LSE: SNG), the respiratory company developing SNG001, an investigational formulation for inhalation containing the broad-spectrum antiviral protein interferon beta, today announces the first presentation of the full data analysis from ... Seite 1
April 7, 2022
Biophytis / Key word(s): MiscellaneousBiophytis provides updates on Sarconeos (BIO101) clinical development 07-Apr-2022 / 08:00 CET/CESTBiophytis provides updates on Sarconeos (BIO101)clinical development  Sarcopenia (SARA) : discussions engaged with FDA for the preparation of a Phase 2-3 program in sarcopenia,...
April 7, 2022
Biophytis / Key word(s): Annual ResultsBiophytis Announces 2021 Operational and Financial Results and Gives Updates on 2022 perspectives 07-Apr-2022 / 08:00 CET/CESTBiophytis Announces 2021 Operational and Financial Results and Gives Updates on 2022 perspectives  Success of Nasdaq IPO in February 2021 €23.9M o...
April 4, 2022
/PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and...
March 29, 2022
/PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunomodulatory therapies for the...
March 2, 2022
/PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunomodulatory therapies for...